Pulmonary Arterial Hypertension and Pregnancy

Pulmonary hypertension in pregnancy has always scared the treating physician and gynecologist due to reported high mortality since ages. The upcoming therapies targeting pulmonary hypertension (calcium channel blockers, nitric oxide, endothelin receptor antagonist, phosphodiesterase type 5 inhibitors) and improvement in hemodynamic monitoring and intensive management in pulmonary arterial hypertension (PAH) specialist centers give a ray of hope to these patients. Termination of pregnancy continues to be a management modality in pregnant patients with PAH. Multidisciplinary approach targeting PAH- and pregnancy-specific therapy in this subset can prove rewarding. Larger multicentric studies in the present era of new pharmacologic agents targeting PAH are required.